Core Viewpoint - The animal health sector experienced a rise of 0.98% on September 30, with *ST Lvkang leading the gains, while the overall market indices also showed positive movement [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3882.78, up 0.52% [1]. - The Shenzhen Component Index closed at 13526.51, up 0.35% [1]. - The animal health sector's individual stock performance is detailed in a table, highlighting various stocks' closing prices and percentage changes [1]. Group 2: Stock Performance - *ST Lvkang (002868) closed at 28.01, with a gain of 3.51% and a trading volume of 16,700 shares, amounting to approximately 46.61 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 9.64, up 1.69% with a trading volume of 412,400 shares [1]. - Jinhe Biological (002688) at 6.69, up 1.67% with a trading volume of 150,600 shares [1]. - KQ Bio (688526) at 17.72, up 1.37% with a trading volume of 32,700 shares [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 3.40 million yuan from institutional investors, while retail investors experienced a net outflow of 28.01 million yuan [2][3]. - The detailed capital flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3]. - For instance, Biological Shares (600201) had a net inflow of approximately 19.60 million yuan from institutional investors, while *ST Lvkang (002868) faced a net outflow of about 6.49 million yuan [3].

证券代码：603566 证券简称：普莱柯 公告编号：2025-039 普莱柯生物工程股份有限公司关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准普莱柯生物工程股份有限公 司（以下简称"公司"）及全资子公司洛阳惠中生物技术有限公司（以下简称"惠中生物"）、洛阳惠中动 物保健有限公司（以下简称"惠中动保"）等单位联合申报的"猫泛白细胞减少症、杯状病毒病、鼻气管 炎三联灭活疫苗（708株+60株+64株）"为新兽药，并于2025年9月29日公示了核发《新兽药注册证书》 （中华人民共和国农业农村部公告第953号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：猫泛白细胞减少症、杯状病毒病、鼻气管炎三联灭活疫苗（708株+60株+64株） 注册分类：三类 主要成分与含量：每头份疫苗中含灭活的猫泛白细胞减少症病毒708株105.7FAID50，含灭活的猫杯状 病毒60株109.0TCID50，含灭活的猫疱疹病毒1型64株107.2TCID5 ...

Core Points - The company, Pulaike, announced the approval of a new veterinary drug by the Ministry of Agriculture and Rural Affairs, which includes a trivalent inactivated vaccine for feline panleukopenia, calicivirus disease, and rhinotracheitis [1] Group 1 - The new veterinary drug is a combination vaccine consisting of strains 708, 60, and 64 [1] - The approval was granted following the review process outlined in the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement [1]

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

Core Insights - The animal health sector experienced a slight increase of 0.46% on September 29, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Shenlian Biological (688098) closed at 10.59, up 1.92% with a trading volume of 68,700 shares and a turnover of 72.32 million yuan [1] - Other notable performers included: - Biological Shares (600201) at 9.48, up 1.50% with a turnover of 503 million yuan [1] - Pulaike (603566) at 13.78, up 1.03% with a turnover of 54.30 million yuan [1] - Zhongmu Shares (600195) at 7.12, up 0.85% with a turnover of 49.02 million yuan [1] Capital Flow - The animal health sector saw a net outflow of 7.69 million yuan from institutional investors, while retail investors contributed a net inflow of 8.08 million yuan [2] - The detailed capital flow for key stocks includes: - Shenlian Biological: net outflow of 5.50 million yuan from retail investors [3] - Biological Shares: net outflow of 7.67 million yuan from retail investors [3] - Pulaike: net outflow of 4.08 million yuan from retail investors [3]

Core Viewpoint - The company, Prike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug aimed at preventing three feline diseases, marking a significant development in its product offerings [1] Group 1: Product Approval - The new veterinary drug is a trivalent inactivated vaccine for feline panleukopenia, feline calicivirus, and feline infectious respiratory disease [1] - The vaccine was jointly submitted by the company and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement from the Ministry of Agriculture and Rural Affairs [1] Group 2: Vaccine Efficacy - The vaccine is designed to prevent feline panleukopenia, feline calicivirus disease, and feline infectious respiratory disease [1] - The immune response is expected to develop within 7 days after the second vaccination, with an immunity duration of 12 months [1]

根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及全资子公司洛阳惠中生物 技术有限公司（以下简称"惠中生物"）、洛阳惠中动物保健有限公司（以下简 称"惠中动保"）等单位联合申报的"猫泛白细胞减少症、杯状病毒病、鼻气管 炎三联灭活疫苗（708 株+60 株+64 株）"为新兽药，并于 2025 年 9 月 29 日公 示了核发《新兽药注册证书》（中华人民共和国农业农村部公告第 953 号）事项。 详情如下： 一、新兽药的基本信息 新兽药名称：猫泛白细胞减少症、杯状病毒病、鼻气管炎三联灭活疫苗（708 株+60 株+64 株） 证券代码：603566 证券简称：普莱柯 公告编号：2025-039 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 注册分类：三类 主要成分与含量：每头份疫苗中含灭活的猫泛白细胞减少症病毒 708 株 10 5.7FAID50，含灭活的猫杯状病毒 60 株 10 9.0TCID50， ...

该兽药作用与用途：用于预防猫泛白细胞减少症、猫杯状病毒病和猫鼻气管炎。免疫产生期为二免后7 日，免疫期为12个月。 智通财经APP讯，普莱柯(603566.SH)发布公告，根据《兽药管理条例》和《兽药注册办法》规定，经 农业农村部审查，批准公司及全资子公司洛阳惠中生物技术有限公司(简称"惠中生物")、洛阳惠中动物 保健有限公司(简称"惠中动保")等单位联合申报的"猫泛白细胞减少症、杯状病毒病、鼻气管炎三联灭活 疫苗(708株+60株+64株)"为新兽药，并于2025年9月29日公示了核发《新兽药注册证书》(中华人民共和 国农业农村部公告第953号)事项。 ...

Core Viewpoint - The company, Pulike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, specifically a trivalent inactivated vaccine for cats, which targets feline panleukopenia, calicivirus, and rhinotracheitis [1] Group 1 - The new veterinary drug is a joint application by Pulike and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The approval includes the issuance of the New Veterinary Drug Registration Certificate, as announced in the Ministry of Agriculture and Rural Affairs' public notice No. 953 [1] - The vaccine is expected to be publicly available by September 29, 2025 [1]

Core Viewpoint - The animal health sector experienced a rise of 1.59% on September 26, with Bio-Pharmaceuticals leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 0.65% and 1.76% respectively [1] Group 1: Market Performance - The animal health sector's individual stock performance showed significant variations, with Bio-Pharmaceuticals closing at 9.34, up by 7.23%, and a trading volume of 1.0367 million shares, resulting in a turnover of 973 million yuan [1] - Other notable performers included Huisheng Biological at 20.68, up by 1.87%, and Ruipu Biological at 20.93, up by 1.60% [1] Group 2: Capital Flow - The animal health sector saw a net inflow of 86.5157 million yuan from institutional investors, while retail investors experienced a net outflow of 44.7995 million yuan [2] - The capital flow data indicates that major stocks like Bio-Pharmaceuticals had a net inflow of 12.63% from institutional investors, despite a significant outflow from retail and speculative investors [3]